WASHINGTON — The FDA's concerns over suicides linked to Forest Laboratories Inc.'s chronic obstructive pulmonary disease (COPD) drug Daxas (roflumilast) had investors only somewhat worried Monday, with shares slipping just slightly. (BioWorld Today)

If upheld on appeal, a federal district judge's ruling Monday that invalidated patent claims related to the BRCA1 and BRCA2 genes held by Salt Lake City-based Myriad Genetics Inc. and the University of Utah Research Foundation could have far-reaching implications for gene patenting and the future of biotechnology product development. (BioWorld Today)